Sanctuary Wealth Advisors LLC cut its holdings in Exact Sciences Corporation (NASDAQ:EXAS) by 16.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 87,180 shares of the medical research company’s stock after selling 16,669 shares during the quarter. Exact Sciences Corporation comprises 3.2% of Sanctuary Wealth Advisors LLC’s holdings, making the stock its 5th largest position. Sanctuary Wealth Advisors LLC owned 0.07% of Exact Sciences Corporation worth $4,108,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Fortaleza Asset Management Inc. purchased a new position in shares of Exact Sciences Corporation in the second quarter worth about $106,000. Krilogy Financial LLC raised its stake in shares of Exact Sciences Corporation by 1,460.0% in the second quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock worth $138,000 after purchasing an additional 3,650 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of Exact Sciences Corporation by 17.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after purchasing an additional 600 shares during the last quarter. Financial Architects Inc raised its stake in shares of Exact Sciences Corporation by 90.0% in the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock worth $152,000 after purchasing an additional 2,035 shares during the last quarter. Finally, Johnson Financial Group Inc. raised its stake in shares of Exact Sciences Corporation by 25.9% in the second quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock worth $172,000 after purchasing an additional 1,000 shares during the last quarter. Institutional investors own 85.65% of the company’s stock.

Several analysts recently commented on the company. Vetr raised Exact Sciences Corporation from a “sell” rating to a “buy” rating and set a $41.07 target price on the stock in a report on Wednesday, August 2nd. Canaccord Genuity reaffirmed a “buy” rating and set a $45.00 target price (up from $42.00) on shares of Exact Sciences Corporation in a report on Wednesday, July 26th. Bank of America Corporation reaffirmed a “buy” rating on shares of Exact Sciences Corporation in a report on Wednesday, July 26th. Roth Capital raised their target price on Exact Sciences Corporation from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Wednesday, July 26th. Finally, Craig Hallum reaffirmed a “buy” rating and set a $46.00 target price (up from $41.00) on shares of Exact Sciences Corporation in a report on Wednesday, July 26th. Eight investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Exact Sciences Corporation has an average rating of “Buy” and a consensus price target of $49.98.

In related news, Director Thomas D. Carey acquired 2,500 shares of Exact Sciences Corporation stock in a transaction that occurred on Thursday, August 17th. The shares were purchased at an average price of $37.71 per share, for a total transaction of $94,275.00. Following the completion of the transaction, the director now owns 60,858 shares in the company, valued at approximately $2,294,955.18. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Graham Peter Lidgard sold 45,775 shares of Exact Sciences Corporation stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $53.60, for a total value of $2,453,540.00. Following the transaction, the insider now owns 272,819 shares in the company, valued at approximately $14,623,098.40. The disclosure for this sale can be found here. In the last quarter, insiders have sold 277,373 shares of company stock worth $12,635,570. 4.00% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “Sanctuary Wealth Advisors LLC Has $4.11 Million Holdings in Exact Sciences Corporation (EXAS)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/13/sanctuary-wealth-advisors-llc-has-4-11-million-holdings-in-exact-sciences-corporation-exas.html.

Exact Sciences Corporation (NASDAQ EXAS) traded down $2.15 during midday trading on Monday, hitting $58.22. The stock had a trading volume of 1,371,238 shares, compared to its average volume of 2,105,743. Exact Sciences Corporation has a 1-year low of $13.05 and a 1-year high of $63.60. The company has a current ratio of 10.34, a quick ratio of 9.98 and a debt-to-equity ratio of 0.01.

Exact Sciences Corporation (NASDAQ:EXAS) last released its earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.07. Exact Sciences Corporation had a negative return on equity of 30.32% and a negative net margin of 60.71%. The business had revenue of $72.60 million for the quarter, compared to the consensus estimate of $65.03 million. During the same quarter last year, the business posted ($0.36) earnings per share. The business’s quarterly revenue was up 158.4% compared to the same quarter last year. research analysts predict that Exact Sciences Corporation will post -1.14 earnings per share for the current fiscal year.

Exact Sciences Corporation Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Stock Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related stocks with our FREE daily email newsletter.